TA Associates is reviving plans to sell French cosmetic treatment company Laboratoires Vivacy, people familiar with the matter said.
The buyout firm is working with BNP Paribas SA and Rothschild & Co. on a potential divestment that could value Vivacy at about 1 billion euros ($1 billion), the people said. It has drawn interest from Asian competitors and other private equity firms, according to the people, who asked not to be identified discussing confidential information.
Founded in 2007, Vivacy specializes in manufacturing injectable hyaluronic-acid dermal filler products, which are available in more than 75 countries, according to its website. TA Associates bought a majority stake in the company in 2019 for an undisclosed sum.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
TA Associates sought to gauge potential interest in the business earlier in the year but nothing materialized, one of the people said.
Deliberations are at an early stage and there’s no certainty they’ll result in a sale, they said. Representatives for BNP Paribas, Rothschild and TA Associates declined to comment, while a spokesperson for Vivacy didn’t immediately provide comment.
Source: BNN Bloomberg
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...




